Revision as of 03:56, 13 February 2026

Abstract

This study investigated the combined efficacy of docosahexaenoic acid (DHA) and Panax ginseng extract for treating Alzheimer's disease (AD). Single-target therapies aimed at clearing amyloid-beta (Aβ) have been largely unsuccessful, shifting attention toward multi-target approaches; among the most promising are DHA and Panax ginseng. Although DHA shows strong efficacy in AD prevention, once neurodegeneration has taken hold, blood-brain barrier (BBB) damage impairs its transport into the brain. Ginseng may counteract this by strengthening the BBB through the Wnt/β-catenin (BAR-1 ortholog in Caenorhabditis elegans) pathway and preventing DHA oxidation via its antioxidant properties, thereby enhancing delivery where it exerts neuroprotective effects. Based on these complementary mechanisms, the present study evaluated whether combined treatment confers benefits beyond either treatment alone using CL2355 (transgenic AD model) and N2 (wild-type) Caenorhabditis elegans. Five experimental groups were compared: two untreated controls (wild-type; AD model) and three AD model groups receiving DHA (5 mM), ginsenoside (10 μg/mL), or both. Treatment effects were assessed through paralysis (mobility), chemotaxis (neurological function), and population growth (reproduction) assays. The combined treatment reduced paralysis by 40% relative to untreated AD worms and 10% beyond either treatment alone, while significantly improving chemotactic function (p<0.01). These results suggest combined treatment holds potential as a multi-target therapeutic strategy, possibly by enhancing DHA absorption by the neurological system and/or targeting AD pathology through compounding mechanisms, though this study cannot distinguish between the two. These promising findings warrant further research using higher-order AD models or assays measuring nervous system DHA absorption.

1.0 Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease that is closely associated with increasing age. Alzheimer’s disease is the main cause of dementia, accounting for 75% of cases [1]. As of 2014, AD impacts more than 35.6 million people worldwide, and this number is estimated to quadruple by 2050 [2,3]. Alzheimer’s disease deteriorates the central nervous system, mitigating language recognition and cognitive behavior [4]. AD damages the neocortex and hippocampus, brain areas that are associated with memory capacity and cognitive behaviors, overall reducing life expectancy and increasing the probability of physical impairment in the elderly [1]. Although the cause of AD has been an area of mass study, it remains not fully understood. According to current studies, it is potentially caused by abnormal accumulation of amyloid-beta(Aβ) aggregation leading to decaying nerve receptors containing depositions of Aβ [5–7]. Aβ is transported to the brain and attacks the neurons, reducing brain functions [8].

Purpose and Importance

Currently, Food and Drug Administration-approved treatments to alleviate Alzheimer’s disease in patients are based on cholinergic and glutamatergic systems in the brain [9]. Cholinesterase inhibitors (CHEI), an enzyme, are the main medicinal drug to mitigate Alzheimer’s disease in patients. CHEI regulates cognitive systems by reducing the failure of acetylcholine, a neurotransmitter communicating information through nerve cells; however, the effectiveness of CHEI is restricted as it induces side effects and lessens in impact as Aβ prevalence increases [4]. NMDA (N-methyl-D-aspartate) receptor antagonists, another class of drugs, have also been used to relieve the progression of AD. N-methyl-D-aspartate receptors play a significant factor in conjunctive transmission and conjunctive flexibility, a foundation of literacy and knowledge retention, central to neurotoxicity [10]. Previous studies indicated that triggering NMDA receptors are involved in AD conjunctive abnormality [11,12]. Consequently, NMDA receptor antagonists attempt to reduce glutamate excitotoxicity, the excessive triggering of neuron amino acid receptors, which leads to neuronal atrophy [13].

Due to the failure of drugs solely targeting Aβ to pass Stage 3 trials, attention is gradually shifting to multi-target drugs or stress protein-based solutions. Multi-target drugs often come in the form of plant extracts and homeopathic therapeutics and may better address AD causes present in its etiology. This study sought to evaluate the efficacy of two established AD treatments, omega-3 fatty acids and ginseng extract, in combination to evaluate efficacy and synergy to contribute to finding new treatments and thus alleviate the burden of AD.

Omega-3 fatty acids (ω-3FAs)

Omega-3 fatty acids (ω-3FAs), especially in the form of DHA (docosahexaenoic acid), are an essential nutrient for brain function and make up 40-50% of total brain mass [14]. Additionally, dietary consumption of ω-3FAs, especially in moderate or high doses, shows promise for slowing down AD progression and restoring executive and hippocampal functioning. Previous studies show that ω-3FAs supplementation decreases AD risk by up to ~64%, and may help restore working memory and executive function in select AD cohorts [15–17]. These outcomes can be largely attributed to ω-3FAs multi-target free radical scavenging, anti-inflammatory, brain barrier supporting, antiapoptotic, and neurotrophic properties [18,19]. When broken down, ω-3FAs create anti-inflammatory specialized pro-resolving mediators, which facilitate brain barrier repair and improve the brain's ability to remove excess Aβ and fibrinogens [20,21]. Furthermore, Mfsd2a (omega-3 neuroreceptor) plays an integral role in the blood-brain barrier (BBB) and pericyte health but decreases with age and cognitive decline. Maintaining a high ω-3FAs index may offset this progression's deleterious effects, further solidifying ω-3FAs’ role in AD prevention and brain health [19,22]. Unfortunately, epidemiological studies indicate that U.S. intake of ω-3FAs is largely inadequate, with the average person only consuming ~0.1-0.2g of DHA or EPA (eicosapentaenoic acid) per day [23]. Equipped with this knowledge, many dementia researchers argue ω-3FAs deficiency to be a leading driver of the current prevalence of AD in the U.S. [16]. The present study sought to spread awareness of ω-3FAs deficiency and contribute to the existing literature on ω-3FAs research.

Outside of targeting hallmark features of AD (i.e., Aβ plagues, neurofibrillary tangles (NFTs), etc.), ω-3FAs may provide benefits that attenuate the cognitive and motor problems associated with AD. In a systematic review including eleven studies with 698 participants, ω-3FAs substantially increased serum brain-derived neurotrophic factor (BDNF) levels in moderate or high doses [24]. For context, BDNF is a neurotrophin that contributes to the formation and maintenance of neuronal synapses. Renowned as a cognitive “substrate”, BDNF plays a vital role in learning, memory formation, emotion, sensory integration, decision making, reward perception, motor function, executive function, and stress response; all of which hold major implications and are negatively affected by AD pathogenesis [25,26]. Unfortunately, various studies found lower levels of BDNF in the brains of AD patients; an association that not only negatively affects cognition but also exacerbates symptoms of AD [27]. Moreover, lower BDNF levels may also contribute to AD risk; however, whether this relationship is causal remains unclear and is an area of future research [28].

Outside of BDNF, ω-3FAs additionally possess anti-inflammatory properties; and more specifically, anti-neuroinflammatory effects as it relates to AD. In the aging brain, misfolded proteins, most readily in the form of Aβ aggregations and NFTs, trigger innate immune responses in the brain’s microglia leading to a cascade of neuro deterioration (Fig. 1). Additionally, ApoE-4, a gene that substantially raises AD risk, upregulates (relative to ApoE-2 or ApoE-3) glial cells through lipid modulation; thus, drastically increasing neuroinflammation [29]. Over the past decades, ω-3FAs were extensively studied and shown to possess a potent anti-inflammatory effect, especially in the field of cardiology and metabolic health [30]. However, recent discoveries show dietary ω-3FAs ability to traverse the BBB where it is not only used as a fuel substrate but also facilitates reduction in neuroinflammation. For instance, in a randomized controlled trial of 33 patients with mild AD, the supplementation of ω-3FAs (2.3 g; DHA-based), reduced levels of phosphorylated tau, and lowered neuroinflammatory biomarkers (interleukin-1 & interleukin-6); all within a relatively short period of 6 months [31].

Figure 1: Pathomechanism sequelae of immune activation (Heneka et al., 2015)

Panax ginseng

Panax ginseng is a perennial plant from the Araliaceae family and was used since 1500 CE in East Asian regions such as Chinese, Korea, and Japan where ginseng is commonly consumed in liquid forms such as tea or wine. Consumption of ginseng is also emphasized due to its health, beauty, and dietary benefits. The indicated restorative impacts of ginseng in tea include invigorating the body and uplifting mood [9]. In recent years, there is also an increase in recognition of ginseng in Western countries. Ginseng is one of the earliest Chinese herbal medicines for the treatment of dementia, such medicines were utilized for the treatment of neurological disorders, showing a low risk for negative interaction when used in medicinal blends [32].

Ginseng contains multi-target effects and is effective in AD prevention and amelioration in multiple human trials [33]. Researchers emphasize the need for further research on ginseng, especially those concerning transport vehicles and drug combinations in AD [32]. Ginsenosides, the main biologically active components isolated from Panax ginseng, act as a neuroprotective agent with potential benefits for AD patients [34]. Moreover, ginseng exhibits anticholinergic activity, neuroplasticity and memory promotion, anti-Aβ, anti-tau, neuroprotective, anti-inflammatory, antioxidant, anti-apoptosis, insulin resistance alleviating, and BBB strengthening properties in in-vitro and animal studies; all of which have major implications for AD patients [32].

Previous research indicates that ginseng may be a suitable therapeutic to mitigate the spread of AD. In transgenic mice models influenced by Alzheimer’s disease, fermented ginseng extract treatment improved memory dysfunction. Repaired cognitive functions are fundamental to reduced Aβ42 brain accumulation, indicating that fermented ginseng ameliorated Aβ42 buildup [35]. Red, black, and white ginseng extracts show an ability to hinder acetylcholinesterase, resulting in reduced hippocampus Aβ oligomer injection-influenced memory anomaly [36]. In this study, ginseng was added in the form of Korean red ginseng (KRG). Compared to other ginseng types, KRG has the most ginsenosides. Korean red ginseng treatment shows improved frontal lobe functions and positive influences on quantitative electroencephalography (a method to record the electrical activity in the brain) [37]. Studies also indicate that KRG benefits cognitive functions and dependable clinical efficiency in patients impacted with AD. Additionally, KRG extract application indicates that cognitive function results can be held up for over two years [38].

Blood-brain barrier (BBB) and nutrient transport

Although previous research shows that ApoE-4 increases the risk of AD exponentially, ApoE’s evolutionary function is less conventionally known. On the fundamental level, ApoE in the brain serves as a regulator of astrocytes and glial cells, helping to modulate inflammation and thus the brain’s ability to fight pathogens and repair. At the beginning of human history, ApoE-4 existed as the sole isoform. Alternate isoforms which increase inflammation less dramatically, namely, ApoE-2 and ApoE-3, appeared only in the presence of a more glucose-based diet facilitated by agriculture. Although ApoE-4 was highly evolutionarily advantageous before the advent of modern medicine; it now poses a leading risk factor for AD pathogenesis, raising AD risk by up to 15-fold in double allele cohorts [39,40].

Many factors attributable to ApoE-4 underpin the drastic increase in risk. For instance, mechanistic research suggests that ApoE-4 binds to receptor LRP1, responsible for Aβ clearance, and thereby elevates levels of Aβ oligomers in the brain by up to 2.7 times [41]. Furthermore, as ApoE-4 binds to LRP1, proteins such as MMP9 and cyclophilin A are released, further augmenting the BBB-degrading consequences of Aβ. This breakdown of the BBB makes the brain vulnerable to neurotoxic proteins (such as plasminogen, auto-antibodies, albumin, fibrinogen, etc.) from the bloodstream, leading to a cascade of neuroinflammation (Fig. 2).

More directly implicated to the present study is the BBB’s role in ω-3FAs transport [20,42,43]. Although ω-3FAs supplementation shows immense efficacy in the prevention of AD, contradictory outcomes regarding efficacy in post-onset cohorts impede the recommendation of ω-3FAs for neurodegenerative disease on a larger scale. For instance, in a randomized controlled trial including 174 patients with mild to moderate AD, a moderate dose of ω-3FAs was unable to improve cognitive outcomes relative to placebo in a six-month period [44]. Although the short study time likely played a part in facilitating inconclusive results, the existing BBB damage of the AD patients may also be a factor. When the BBB becomes compromised, the ability of ω-3FAs transporters to utilize and uptake ω-3FAs drastically deteriorates. For instance, although the brains of young adults readily uptake ω-3FAs, regardless of ApoE status; older adults, especially those with ApoE-4 and/or AD, fail to uptake ω-3FAs at the same rate [15]. This pattern is observed in a randomized controlled trial that concluded supplementation with DHA was significantly less effective at mitigating AD symptoms in ApoE-4 cohorts compared to those with ApoE-3 [45].

However, multiple methods were proposed to increase ω-3FAs bioavailability in the brain. One such approach is prescribing ω-3FAs synergistically with applicable antioxidants and/or polyphenols. For instance, a recent study looking to improve cognitive function in older but otherwise healthy adults combined standard ω-3FAs with carotenoid and vitamin E and attributed their positive results to the addition of antioxidants inducing superior bioavailability [17]. 

Although antioxidants likely work synergistically with ω-3FAs in the aforementioned study, combining ω-3FAs with ginseng may have even greater effects since ginsenosides may also strengthen the blood brain barrier and specifically address the neurodegenerative cascade that impairs Mfsd2a, the primary transporter of DHA to the brain. Specifically, Ginsenoside Rg1 directly activates the Wnt/β-catenin pathway, the direct transcriptional regulator of Mfsd2a, thus creating more DHA transporters [46]. Moreover, ginseng may halt the broader BBB degradation entirely by inhibition of MMP-9, an enzyme that downregulates Mfsd2a in APOE4 carriers, and through its ability to cross the blood brain barrier and reduce the neuroinflammation as the center of the neurodegenerative cascade [47]. Preliminary studies suggest that ginseng modulates lipid metabolism and thus reduces adipose disposition in the C. elegans model [48]. Human trials also support this claim, albeit to a limited extent as current studies are subject to substantial limitations and show contradictory results [49]. Regarding ω-3FAs specifically, ginseng extract shows extended health span by upregulating ω-3FAs (in the form of lipoic acid) metabolism signaling pathway in C. elegans; however, it is unclear whether this effect translates to DHA and EPA. Together, these results suggest that ginseng extract positively modulates the usage of ω-3FAs through upregulating metabolism and preventing adipose deposition which by extension increases ambient ω-3FAs levels and transport to the brain [50].

Figure 2. Schematic representation of the blood–brain barrier (Abbott et al., 2010)

Caenorhabditis elegans

Caenorhabditis elegans are commonly used experimental organisms for genetic and genomic analysis research. This is attributed to their cellular simplicity, genetic amenability, inexpensiveness, and homology to humans possessing complex biochemical pathways and genes in which mutations are correlated with AD [51]. The nervous system of C. elegans consists of 302 neurons that control behaviors such as locomotion, allowing processes and mechanisms to be traced at the level of individual neurons [52]. This neuronal connectivity in C. elegans is advantageous in modeling learning and memory impairments seen during AD [53]. The short life span of 2-3 weeks allows for the observation of neurodegeneration in nematode cohorts during the entire adult life of the organism [52]. Previous studies utilized its transparent body for visualization of all cell types and expression of fluorescent proteins in specific cells and tissues, useful for in vivo investigation of neuronal death or protein aggregation processes [52]. Although previous research uses ginseng extract and Omega-3 supplements separately on the C. elegans Alzheimer’s model, the combination of both factors remains unknown.

Previous research

To date, there are no AD studies combining ω-3FAs (in DHA, ALA or EPA form) with ginseng. However, there have been two notable studies using the combined treatment in different contexts. A double-blind randomized controlled trial researched the combined treatment alongside green tea catechins and found significantly increased performance on cognitive tests and increased activation in relevant brain regions via fMRI [54]. A later study using ginseng and ω-3FAs was conducted on ADHD children; and found that the combination significantly alleviated ADHD symptoms with benefits beyond the seldom use of either ginseng or omega 3; possibly indicating a synergistic effect [55]. However, no study investigated the potential connection between ginseng and increased ω-3FAs absorption in the brain. 

Research question & hypothesis

The present study researched the efficacy of a combination of Docosahexaenoic acid (DHA) and Panax Ginseng extract for the treatment of Alzheimer's Disease (AD). Based on both the comprehensive mechanisms the combined treatment addresses (see previous sections: Panax Ginseng and Omega-3 fatty acids) and the potential for ginseng to increase DHA absorption in the nervous system (see previous section: Blood-brain barrier and nutrient transport), the researchers of this study hypothesize that a combination of ginseng extract and omega 3s would exert a synergistic effect on alleviating Aβ toxicity in CL2355 (transgenic AD model) to an extent greater than that of either treatment alone. In the present study, this translates to a higher percentage of unparalyzed worms following temperature upshift, greater population growth (measured as total number of C. elegans over time), and a higher chemotaxis index. 

2.0 Materials and Methods

Creating M9 buffer

Using a top loading balance, 1.5 g of KH₂PO₄, 3 g of Na₂HPO₄, and 2.5 g of NaCl was dissolved in a 500 mL of distilled water in a graduated cylinder. The solution was then sealed with aluminum foil and autoclaved for 20 minutes. Next, 1 mL of 1 M MgSO₄ was added to the solution. The final solution was stored at room temperature and sterilized using an autoclave prior to each use.

Creating ginsenoside stock solution (10 mg/ml)

Five grams of ginseng extract was measured using a top loading balance. Next, 50 mL of distilled water was measured into a graduated cylinder, mixing it with the ginseng extract in the graduated cylinder until fully dissolved. The solution was then autoclaved at 120°C for 2 hours before being transferred to the test tube and stored in a dark and cool environment. If necessary, the solution was repeatedly mixed before each use.

Creating Omega-3 stock solution (500 mM)

Utilizing a top-loading balance 8.2g of DHA omega-3 was measured in an Erlenmeyer flask using a top-loading balance. In a graduated cylinder, 50 mL of sterilized M9 solution was measured. Using 1.5 mL Tween 80, the measured omega-3 was dissolved. The water and fatty acid emulsion was transferred into a vial and vortexed until it was fully homogeneous. The stock solution was stored in a light blocking tinted vial and placed in a dark and cool environment until its usage. Before each use, a vortex was used to ensure a homogeneous mixture of the treatment.

Creating Nematode Growth Media (NGM) agar plates

The C. elegans were cultured in the Nematode Growth Media (NGM) agar plates with various concentrations of the tested treatments. The Petri dishes were labeled by group names per distinct treatment concentrations and strains according to Table 1. The NGM (provided by Carolina Biological) in solid form was melted into liquid form for usage. First, the bottle was uncapped about halfway to release steam and pressure. The NGM agar was then added into the microwave for 30 seconds in intervals of 15 seconds, checking each time until adequately melted (alternatively a water bath at approximately 100℃ was used if time permitted). Gloves were used when taking the agar out of the microwave, properly shaking it to ensure no solids remain (agar should be a dark-yellow liquid). Then, the agar was allowed to cool for a few minutes with caution of re-solidification in cases of excessive cooling.

Half of the NGM agar was dedicated to ginseng groups by transferring them to a separate graduated cylinder. A 1000x dilution of ginsenoside solution (0.18 mL) was performed using 180 mL of NGM agar as the solvent. Then, the agar was poured into the Petri dish very quickly, covering the lid of the Petri dish and tapping the bottle to avoid possible contamination. The aforementioned procedure was repeated for all Petri dishes with a waiting time of 15-20 minutes until agar solidified in each dish prior to refrigerator storage for 24 hours before usage (keeping the Petri dish upside down to prevent condensation from falling on the agar).

Each plate was then spotted with E. coli OP50 grown for 24 hours in LB Media. Upon transferring, plates were dried for an additional 24 hours. The previously made omega-3 stock solution was diluted from 1mL to 5 mM with sterilized water to a final volume of 100 mL (100x dilution). Then, a dispersion of 0.1 mL of DHA omega-3 aliquot to the solidified and spotted NGM in Groups CL -G/+O, and CL +G/+O was done using a spreader. Upon administration of treatment in each Petri dish, the mediums were allowed to dry for another 24 hours.

Table 1: Experimental Setup

Toothpick technique C. elegans Transfer

A blunt dissecting probe, acting as a pick for C. elegans transfer, was sterilized on a flame. A bead of OP50 was collected from an empty place to make the point sticky. Gently touch the worm selected using the OP50 coated probe. When the worm disappeared, it was on the probe. The worms were placed on the destination place by gently rolling the probe's tip until it became free. The worm was zoomed in on using the microscope to ensure that it was not damaged after the transfer and only the selected worm or egg was transferred.

Creating bacteria agar

The table was cleaned before beginning and preparing the materials for the study. All safety precautions were followed as well. A weighing paper was folded to make it easier to handle. On a weighing boat on a scale, 17.5 g of premix LB Agar powder was weighed. This powder was transferred to an Erlenmeyer flask and distilled water was added until reaching a final volume of 500 mL. The bottle cap and the top were sealed with aluminum foil tightly. The solution was then autoclaved in the liquid setting for 20 minutes. Following the autoclaving, the agar was cooled to about 55℃. A thin layer of LB agar was poured into each Petri dish, ensuring the liquid was properly and evenly spread. After putting on the lid of the Petri dishes, each plate was left to cool down until solidification. After 24 hours of the solidification process, the dish was flipped to avoid the condensation falling onto the agar. After this, the plates were placed in plastic bags in the refrigerator at 4℃.

Bacterial aseptic technique

E. coli OP50 (Source: https://cgc.umn.edu/strain/OP50) was used to feed C. elegans

(Sourced: CL2355 strain: https://cgc.umn.edu/strain/CL2355 and N2 strain: https://cgc.umn.edu/strain/N2) and placed in all Petri dishes. A rubber tube was connected to the valve of the gas and the valve of a Bunsen burner. Once the gas ignited, a match was lit and placed over the gas. The inoculation loop was sterilized by passing the tip and the neck of the inoculation loop through the flame. After the inoculation loop cooled, it was used to scoop the agar from a bacterial colony. The bacteria were streaked across the surface of a new Petri dish, ensuring that there was no excessive pressure put on the agar to refrain from breaking it. After, the lid was placed back on to the Petri dish and flipped upside down in the incubator to ensure that the accumulated condensation does not fall on the agar. Following two days of the Petri dishes being incubated, parafilm was wrapped around the sides of the Petri dish and placed into the fridge to store for later use. Before and after each process, diluted bleach was used to sterilize all surfaces.

Spotting Petri dishes with E. coli OP50

A 0.5 cm x 0.5 cm square chunk of agar with E. coli OP50 was cut using forceps or other sterilized metal. Sterilized forceps were used to grab a piece of agar. The agar was placed into the middle of the premade NGM plates. Each chunk was gently placed into its respective Petri dish. Before and after cutting and transferring each chunk, disinfectant tools were used to prevent contamination.

Conducting the paralysis assay

After 48 hours of C. elegans culturing, the temperature was either adjusted to 27℃ (for Trial 1) or 30℃ (for Trial 2). To ensure that the plates reached the temperature at the same time, the plates were not stacked on each other. After 24 hours of temperature upshift, the scoring of paralysis was performed for every two hours until all nematodes were paralyzed. Paralyzed nematodes were transferred to a part of the plate that was not spotted to refrain from scoring them again. In C. elegans, the head of nematodes is last to become paralyzed while the tail is first, restricting its movement. The C. elegans were considered paralyzed when they were unable to move, excluding its head. Nematodes that rarely voluntarily move were poked using a worm picker. If C. elegans did not show full movement, they were considered paralyzed.

Testing for Population Growth

A 24 well plate’s first column was labeled “WT”, the second column “CL -G/-O”, the third column “CL -G/+O”, the fourth column “CL +G/-O”, and the fifth column “CL +G/+O”. Four wells were used for each group. First, 1.0 mL of ginsenoside NGM was poured into the columns of CL +G/-O and CL +G/+O. Then, 0.1 mL of DHA omega-3 aliquot was pipetted to the solidified and spotted NGM in the columns CL -G/+O and CL +G/+O. Then, C. elegans were chunked into each column containing NGM. Every day for one week, the amount of C. elegans was recorded under a compound microscope. For Trial 1 of the assay, 10 μL ginseng was spread on top of the NGM for the treatment groups that required it. For Trial 2, ginseng was diluted into the NGM following the previous procedure.

Conducting the Chemotaxis Index Assay

Seven days before conducting the chemotaxis, C. elegans from each group were transferred to similar treatment plates to allow the C. elegans to culture. These plates were regarded as the treatment plates. Two days before the chemotaxis, a marker was used to divide each of 5 NGM Petri dishes into 4 equal quadrants, and a circle was created from the origin with a 1 cm radius. Then, another circle was created from the origin with a 2 cm radius. 10 µL of E. coli, acting as an attractant, was pipetted onto quadrant 1 and quadrant 3 of the chemotaxis plate. These 5 Petri dishes with the absence of treatment were regarded as the chemotaxis plates.

A micropipette was used to pipette 2 mL M9 on the treatment plates. The treatment plate was gently angled to cover all surface area to ensure that all nematodes were cleansed. A pipette was used to pipette 1 mL of the previously made worm solution in a microcentrifuge tube. The solution was centrifuged for 6,600 rpm for 10 seconds. After the centrifugation, the remaining M9 was removed. One mL M9 was pipetted in the centrifuge tube and the tube was turned to ensure that all nematodes were cleansed. The process was repeated three times. After, the volume of the supernatant was reduced to 100 μl and centrifuged for another 10 seconds. A pipette was used to transfer 2 μl of nematodes onto the chemotaxis plates.

After the 60 minute cleansing period, the nematodes were used. A micropipette was used to transport 2 μL of the nematode solution from the centrifuged solution to the center of the chemotaxis plate, or the intersection of the perpendicular lines drawn. Immediately after, a recording device was set directed towards the chemotaxis plates in a compound microscope, and a 60 minute video was recorded. After 60 minutes, the chemotaxis plates with the nematodes were placed in an incubator with a controlled temperature of 4 °C. The number of nematodes that passed through the circle with a 1 cm radius and moved towards the attractant zone or control zone and the time it took was recorded in Microsoft Excel corresponding with their respective quadrants. The process was repeated, replacing the treatment solution with sole control treatment. This Petri dish was regarded as the control plate. The chemotaxis assay was performed in quadruplicate.

Safety

Proper lab safety, including wearing gloves, goggles, and tied hair during the experimentation process, was fulfilled especially when conducting bacterial works. The tabletop working area was cleansed with a diluted bleach solution before and after experimentation along with the sterilization of all instruments at the end of the trial period. All Petri plates were sealed with parafilm during experimentation and autoclaved at 120 ℃ and 100 kPa for 20 minutes as part of the disposal procedure. Tools in contact with cultures were also soaked in 10% bleach and sterilized with heat as a segment of the disposing process. Hands were washed after any bacterial work. Three days of safety training specifically for bacterial works and the presence of experienced supervisors were ensured whilst dealing with microorganisms and the flame or gas of a Bunsen burner required for sterilization.

Three days of safety training specifically for bacterial works and the presence of experienced supervisors were ensured while dealing with microorganisms and the flame or gas of a Bunsen burner required for sterilization of tools. Most substances utilized in the study possessed a biosafety level BSL-1 and deemed “not hazardous” under the criteria of the federal OSHA Hazard Communication Standard 29CFR 1910.1200, and Regulation (EC) No 1272/2008 (GHS). Nonetheless, substances specifically can be dangerous when ingested, inhaled, or especially in cases of in contact with eyes (skin contact and inhalation do not pose serious harm unless it is done excessively or if the researcher feels unwell after exposure) so precautionary safety such as protective gloves, clothing, and above all else eye protection was adhered to.

Data Analysis

Data was collected, stored, and analyzed using Microsoft Excel. Data was shown using scatter plots and bar graphs in which the x values were time in hours, time in days, and group names and the y values were not paralyzed C. elegans as a percentage, number of C. elegans, and chemotaxis index. The median paralysis time was conducted using a Kaplan–Meier survival analysis. In the paralysis assay, the number of non-paralyzed C. elegans on each plate was converted into a percentage. The standard mean of error was calculated and represented as error bars added using Microsoft Excel. To calculate significance, one-way ANOVA followed by Tukey HSD was done using https://astatsa.com/OneWay_Anova_with_TukeyHSD/. Significance was determined using p-values in which a p-value less than 0.05 was considered significant. Chemotaxis index was determined using the following formula:

CI = (number of worms in attractant zone - number of worms in control zone)/total number of scored worms

Results

Figure 3. Trial 1 Paralysis Assay of WT and CL2355 with respective treatments. Following 48 h of incubation at 25℃, the temperature was increased to 30℃ for 31 h. The number of unparalyzed nematodes was converted to percentages (n=10).

In the C. elegans strain CL2355, as the temperature rises, Aꞵ peptide production increases in nematode muscles, leading to paralysis. CL-G/-O (the negative control group) had the lowest percentage of unparalyzed worms 48 hours after the temperature upshift. CL -G/+O had the highest percentage of unparalyzed worms compared with the negative control group, at 70% 48 hours after the temperature upshift. Additionally, CL +G/-O and CL +G/+O showed similar effects, with the percentage of unparalyzed worms remaining identical over time. Throughout the assay, all treatment groups exhibited a higher percentage of unparalyzed nematodes, indicating alleviation of the effects of Aβ aggregation. The wild-type C. elegans (WT) does not produce Aꞵ peptides, so the nematodes did not exhibit paralysis following a temperature upshift.

Figure 4. Trial 1 Population Growth with respective treatments. Data collection lasted over 8 days. Error bar values represent mean ±SEM. Statistically significant comparisons (p<0.05) are represented with different letters.

Figure 4 shows population growth throughout the whole assay, with CL +G/-O and CL +G/+O showing higher populations compared to WT from Day 5. At Day 6, CL +G/+O (combined treatments) had a statistically significantly higher population than the CL -G/+O group. Similarly, at Day 7, CL +G/-O had statistically higher growth than WT along with Day 8, demonstrating a significantly higher population compared to CL -G/+O.

Figure 5. Chemotactic response of WT and CL2355 with respective treatments. Chemotactic plot displaying chemotaxis index of WT and CL2355 (+/-) omega-3 and (+/-) ginseng. Error bars = ±SEM. p<0.05 is represented with different letters.

The results shown in Figure 5 indicate that WT (N2 wildtype) had the greatest chemotaxis index compared to all other groups. CL -G/-O, the negative control group, had the lowest chemotaxis index, which was statistically significant when compared to the CL -G/+O group, CL +G/-O, and CL +G/+O. Out of the groups expressing Aꞵ peptides, CL +G/+O had the greatest chemotaxis index, with statistical significance when compared to CL -G/-O and CL -G/+O. The CL +G/-O group had the next greatest chemotaxis index (0.222), followed by CL -G/+O (0.188).

Figure 6.  Trial 2 Paralysis Assay of WT and CL2355 with respective treatments. Following 48 h of incubation at 25℃, the temperature was increased to 30℃ for 31 h. The number of unparalyzed nematodes was converted to percentages (n=10).

The results of Figure 6 are consistent with that of Trial 1 in which all treatment groups had a higher percentage of unparalyzed C. elegans compared to CL -G/-O. WT had the lowest percentage of unparalyzed worms throughout the trial, except at Hour 0. Among all treatment groups with C. elegans exhibiting Aβ aggregation, CL +G/+O (combined treatment) had the highest percentage of unparalyzed C. elegans (80%) at 31 hours following the temperature upshift. The CL-G/+O and CL+G/-O groups both had 70% unparalyzed C. elegans 31 hours after a temperature upshift. Therefore, treatment with sole ginseng, sole omega-3, and a combination of ginseng and omega-3 all showed alleviation of Aβ aggregation effects, with the combination treatment exhibiting the greatest effect in Trial 2 of the paralysis assay.

Figure 7. Trial 2 Population Growth Assay. Data collection lasted over 9 days. Error bar values represent mean ±SEM. Statistically significant comparisons (p<0.05) are represented with different letters.

Figure 7 shows that WT had the highest population number throughout the assay. All groups exhibiting Aβ aggregation had significantly lower populations than WT on Days 8 and 9. CL-G/-O (the negative control group) decreased in population number as the assay progressed. Within the groups exhibiting Aβ aggregation, CL +G/+O (combined treatments) displayed the highest population throughout the whole trial, other than Day 5.

Discussion

The results of this study generally support the original hypothesis, suggesting that a multitarget treatment consisting of Panax ginseng extract and ω-3FAs confers a synergistic, or at a minimum additive, effect in alleviating Aβ toxicity. This conclusion is supported by the outcomes in Fig. 6, where CL +G/+O (combined treatment) displayed 40% and 10% lower rates of paralysis relative to untreated CL2355 worms (CL -G/-O) and sole treatment groups (CL -G/+O & CL +G/-O), respectively. Lower rates of paralysis in AD worms indicate mitigation of Aβ oligomer production and/or attenuation of its deleterious effects [56]. Although researchers proposed the amyloid cascade theory in 1992 as the guiding framework of AD etiology, many now deviate from or modify this original hypothesis, forming numerous schools of thought, each backed by extensive research, such as blood-brain barrier breakdown, mitochondrial dysfunction, and the Aβ Oligomer Hypothesis [57–59]. The latter directly relates to interpreting paralysis in the C. elegans model of AD. Put simply, the Aβ Oligomer Hypothesis identifies Aβ oligomers, instead of Aβ plaques, as the key neurotoxic species driving neuroinflammation, neuron damage, and eventually AD pathogenesis. In C. elegans models of AD, researchers typically observe paralysis without visible deposition of Aβ plaques, concluding Aβ oligomers as the primary cause of paralysis [56]. Over the years, hundreds of trials have identified drugs that work to clear Aβ, but none, with the exception of Donanemab, has improved outcomes to a clinically significant extent. Researchers attribute the relative effectiveness of Donanemab to its unique ability to specifically target neurotoxic forms of Aβ, unlike treatments that target harmless or even protective Aβ species indiscriminately [60]. However, with the drug currently costing $32,000 per year and proving effective only in the early stages of AD, it has a long way to go before widespread clinical adoption [61]. As a combination of Panax ginseng extract and ω-3FAs similarly targets neurotoxic forms of Aβ (i.e., Aβ oligomers), these treatments may serve as a viable alternative with benefits beyond Aβ clearance due to their multitarget nature.

The paralysis assay was then followed up with a chemotaxis assay to see whether Aβ attenuation translates to neurological function in areas outside of movement. The assay integrates sensory perception, motor output, learning, and memory, making it a comprehensive marker of neurological function and neurotoxicity. The C. elegans strain CL2355 produces Aβ in the neurons through the synaptobrevin ortholog (snb-1) promoter, leading to flaws in 5-Hydroxytryptamine (5-HT) sensitivity, neuronal manners, and chemotaxis. Figure 5 shows that the nematodes treated with a combined application of ginseng and ω-3FAs had the greatest increase in chemotactic ability out of the groups containing nematodes expressing Aꞵ (p<0.01). Ginseng administered alone showed similar effects when compared to DHA administered alone, both with scores significantly higher than the CL2355 group, with no external treatment, and significantly lower than the combined treatment group. These findings suggest that the combined treatment of ginseng and ω-3FAs exerts a synergistic or additive neuroprotective effect and partially restores performance in complex neurological tasks. 

The combined treatment had marginal, non-statistically significant effects on population growth (Fig. 7). This indicates a limitation of the combined treatment for areas outside of neurological function. However, as incomplete sterility is a unique characteristic of the CL2355 strain and as some AD strains exhibit normal reproductive function, it is unclear whether its impaired reproduction is directly a result of AD pathology. 

Limitations and Future Research

Treatment Delivery Method

Even with promising preliminary results, the present study results are not without its limitations. Firstly, Trial 1 of the paralysis assay (Fig. 3) displays results that contradict those of Trial 2 (Fig. 6). Specifically, Fig 3. shows that the combined treatment of ginseng and ω-3FAs (30% less paralysis relative to Cl2355 control) exerts weaker anti-paralytic effects than the sole treatment of omega-3 (40% less paralysis relative to Cl2355 control). These contradictory results are likely due to the method of ginseng delivery. In the first trial, ginseng was infused within NGM (nematode growth medium) agar instead of being spread across the surface (the delivery method used for omega-3). Initially, this approach aimed to control the treatment volume (i.e., amount of water) across groups and address concerns that volatile ginsenosides might denature upon contact with tween 80 (a surfactant and emulsifier used in the omega-3 treatment solution). Since this delivery system likely impeded proper ginseng absorption, it was replaced with a spreading method in Trial 2, as per prior research. With this change, Trial 2 displayed markedly higher efficacy in both the sole ginseng group and combined treatment (10% and 10% reduction in paralysis in Trial 1, compared to 30% and 40%, respectively). Moreover, this theorized improvement in absorption correlates with the increased population in the Trial 2 ginseng group (CL +G/-O; relative to groups within each trial) compared to Trial 1. Thus, future studies should  adjust delivery methods to spreading treatments in order to optimize treatment absorption. 

C. elegans Strain

Concerns arose regarding the C. elegans strain utilized to test treatment effects within trials. The researchers of the present study chose the Cl2355 strain in light of its incomplete sterility (suitable for population assays) and its prior use in a chemotaxis assay [56]. Regarding the paralysis assay, the Cl2355 strain demonstrates temperature-induced pan-neuronal expression of Aβ, meaning that although heat can increase Aβ production, it is not the sole determinant [62]. In contrast, the CL4176 strain is better equipped due to its strictly temperature-dependent and has extensive use in previous studies for testing paralysis [56]. Due to a lack of resources, the researchers of the present study chose Cl2355 as the sole AD model. However, future research should use strain CL4176 and Cl2355 in combination to address limitations within the paralysis assay. 

Data Significance

For both paralysis trials, data significance (p<0.05) could not be determined due to each group having only one sample (n=10/group). Although this experimental design was formulated in alignment with some previous research, demonstrating significance can allow the experiment to undergo more rigorous scrutiny. To address this concern, future research involving C. elegans paralysis should be performed in triplicate per assay and subjected to data analysis through ANOVA in order to increase validity.

Population Assay

Similar to paralysis, results of the population assay (Fig. 4 & Fig. 7) also notably differed between trials. Likewise, Trial 1 (Fig. 4) was subject to similar oversights as Trial 1 of paralysis, such as the delivery method of ginseng treatment (CL +G/-O and CL +G/+O). Further exacerbating these limitations, nematodes lacked a consistent food source throughout the experimental duration. Although C. elegans were transferred from agar spotted with OP50, this limited food source may have been depleted through the trial. Considering that both Omega-3 and ginseng are extensively researched to increase metabolism in both human and animal models, OP50 may have been depleted sooner in treatment groups, thereby inducing a starved state [50,63]. Hence, the rapid depletion of food potentially acted as a compounding variable for observed results, and should be preventable in future replicational studies with more undeviating constant feedings. Additionally, group A became contaminated at around day 4, which resulted in a final population lower than that of CL -G/-O (Cl2355 without treatment). Trial 2 addressed these limitations by changing ginseng administration to spreading and implementing more rigorous sterilization and resulted in outcomes, regarding WT and CL -G/-O (Fig. 6), consistent with prior research [56]. 

Chemotaxis Assay

Although without much of the methodological confounders present in Trial 1 of the Paralysis and population growth assays (poor ginseng delivery, inadequate food source, etc.), the chemotaxis assay presents its own unique limitations. Previous studies have suggested that C. elegans at different life stages can respond differently to certain stressors [64]. Previous research recommends using C. elegans in the young adult stage when analyzing chemotactic ability. Although the nervous system is fully developed in C. elegans at the end of the L1 life stage, there are some intermediate changes within the chemosensory neurons in nematodes at the L4 life stage [65]. Earlier studies have used bleach to synchronize C. elegans' life stages; however, bleach synchronization was implemented in this study due to constraints of laboratory equipment available to student researchers. However, variance in nematode life stages was minimized by having a relatively high sample size in each quadrant. Additionally, most studies performing chemotaxis assay apply an anesthetic (i.e. sodium azide) to paralyze C. elegans upon entering the quadrant. However, most, if not all, anesthetics, such as sodium azide, are highly volatile and are quickly absorbed by the skin within a few seconds of exposure, leading to potential poisoning. To mimic the results of anesthetics, a 60-minute video was taken of the chemotaxis plates where the first quadrant that each C. elegans entered was recorded as their final quadrant, and the recorded nematodes were transferred to refrain from rescoring.

C. elegans Model

C. elegans as a model of AD possesses notable limitations. The organism lacks several features central to AD pathology, including the APOE gene, a BBB, complex mammalian neurophysiology (hippocampus, cortex, BDNF signaling), tau phosphorylation (in Aβ-expressing models), and a human-like microbiome [52]. These absences are directly relevant to the mechanisms proposed in this study. For instance, ginseng's ability to ameliorate cognitive defects in mouse AD models depends partly on restoring lactobacillus dominance—a mechanism absent in C. elegans [66]. More critically, the BBB-mediated mechanisms inferred to underlie ginseng's enhancement of DHA transport to the brain—a central component of the original hypothesis—cannot be rigorously tested in an organism lacking a BBB. Similarly, although C. elegans possesses a Wnt/β-catenin analog (BAR-1, a pathway activated by ginsenosides), it lacks the Mfsd2a transporters that Wnt/β-catenin transcriptionally regulates, which substantially limits the ability of the present study to corroborate the proposed mechanism by which ginseng enhances DHA absorption [52]. 

Nevertheless, C. elegans remains valuable for rapid preclinical screening. Its short lifespan and genetic versatility (e.g., temperature-induced Aβ secretion) make it well-suited for initial evaluation of novel treatments [52]. Although C. elegans lacks mammalian-specific genes such as BDNF, it retains the majority of evolutionarily conserved genes, including those involved in klotho production, whose expression is upregulated by ginseng [67,68]. Moreover, as the first study to evaluate DHA treatment in a C. elegans AD model, the present work expands the existing literature and establishes a foundation for future research. To further leverage the C. elegans model, future studies should test the combined treatment on tau-expressing and gene-knockout strains to elucidate underlying mechanisms. Western blot analysis using anti-Aβ 6E10 and anti-oligomer A11 antibodies should also be performed to confirm that the combined treatment specifically targets Aβ oligomers. Nevertheless, when faced with promising findings, the limitations of C. elegans underscore the importance of progressing to higher-order organisms. 

Synergistic or Compounding? An Area of Future Research

Despite the combination of ginseng and DHA outperforming either treatment alone on all tested measures, this study cannot definitively conclude whether these effects were due to compounding properties of each treatment or increases in DHA absorption due to ginseng. The interpretation that attributes these results to compounding properties is convincing since Ginseng and DHA ameliorates AD symptoms and Aβ through both similar and different mechanisms. For instance, both treatments decrease neuroinflammation and, in some cases, use similar mechanisms (e.g. inhibiting NF-κB signaling); but decreasing neuroinflammation through the Nrf2/ARE pathway is a property of ginseng unavailable to DHA while producing specialized pro-resolving mediators is a property of DHA unavailable to ginseng [10,69]. In effect, this means that the combined treatment casts a wider net, tackling AD pathology from more angles. However, as the present study speculates, the promising outcomes of the combined treatment may also result from ginseng increasing DHA absorption by the nervous system due to mechanisms such as the Wnt/β-catenin pathway and its antioxidant properties [17,32]. Thus, the present study presents the relationship between ginseng and DHA-absorption as a gap in the current literature. Although unavailable to researchers of the present study, future investigations using C. elegans can should assess the amount of DHA absorbed; Some options include using lipophilic dyes, Gas Chromatography-Mass Spectrometry, or monitoring the expression of fat-related genes [70]. 

Conclusion

This study provides promising preliminary evidence that a combined treatment of Panax ginseng extract and DHA alleviates Aβ toxicity more effectively than either treatment alone. The combined treatment appears to ameliorate Aβ oligomer toxicity, as suggested by the paralysis assay, and partially restore complex neurological function, as suggested by the chemotaxis assay. However, limitations including the model organism, confounding variables, and insufficient statistical power for certain assays underscore the preliminary nature of these findings. Moreover, this study could not determine whether the observed benefits arose from complementary mechanisms of the two treatments or from ginseng enhancing DHA absorption in the nervous system. Beyond its empirical findings, this study advances a mechanistic hypothesis that ginsenosides may enhance DHA bioavailability via the Wnt/β-catenin pathway and antioxidant protection, which, if validated in future research, could reframe the clinical utility of DHA supplementation in post-onset AD where BBB damage currently limits efficacy. Lastly, as the first study to evaluate DHA treatment in a C. elegans AD model, the present work demonstrates that DHA's established neuroprotective effects in mammalian models are reproducible in C. elegans model of AD. Given the growing global burden of AD and the prohibitive cost and limited efficacy of current treatments, accessible multi-target treatments warrant urgent investigation. Next steps should include directly measuring whether ginseng increases DHA absorption, achievable in C. elegans through lipophilic dye tracking or gas chromatography-mass spectrometry, followed by progression to higher-order AD models such as APP/PS1 mice. 

References

[1]       Qiu C, Kivipelto M and Von Strauss E 2009 Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention Dialogues in Clinical Neuroscience 11 111–28

[2]       Anstey K J, Cherbuin N, Herath P M, Qiu C, Kuller L H, Lopez O L, Wilson R S and Fratiglioni L 2014 A Self-Report Risk Index to Predict Occurrence of Dementia in Three Independent Cohorts of Older Adults: The ANU-ADRI ed J C Zheng PLoS ONE 9 e86141

[3]       Zhou L, Huang P-P, Chen L-L and Wang P 2019 Panax Notoginseng Saponins Ameliorate Aβ-Mediated Neurotoxicity in C. elegans through Antioxidant Activities Evidence-Based Complementary and Alternative Medicine 2019 7621043

[4]       Sharma K 2019 Cholinesterase inhibitors as Alzheimer’s therapeutics (Review) Mol Med Rep 20 1479–87

[5]       Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M and Mahmoudi J 2015 Amyloid-beta: a crucial factor in Alzheimer’s disease Med Princ Pract 24 1–10

[6]       Deng X, Zhao S, Liu X, Han L, Wang R, Hao H, Jiao Y, Han S and Bai C 2020 Polygala tenuifolia : a source for anti-Alzheimer’s disease drugs Pharmaceutical Biology 58 410–6

[7]       Bredesen D E 2016 Inhalational Alzheimer’s disease: an unrecognized—and treatable—epidemic Aging (Albany NY) 8 304–13

[8]       Soni D and Galluci L 2023 The Causes and Effects of Alzheimer’s Disease J Stud Res 12

[9]       Kim H-J, Jung S-W, Kim S-Y, Cho I-H, Kim H-C, Rhim H, Kim M and Nah S-Y 2018 Panax ginseng as an adjuvant treatment for Alzheimer’s disease Journal of Ginseng Research 42 401–11

[10]     Liu J, Chang L, Song Y, Li H and Wu Y 2019 The Role of NMDA Receptors in Alzheimer’s Disease Front. Neurosci. 13

[11]      Paoletti P 2011 Molecular basis of NMDA receptor functional diversity European Journal of Neuroscience 33 1351–65

[12]     Kodis E J, Choi S, Swanson E, Ferreira G and Bloom G S 2018 N-methyl-D-aspartate receptor–mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer’s disease Alzheimer’s & Dementia 14 1302–12

[13]     Mark L P, Prost R W, Ulmer J L, Smith M M, Daniels D L, Strottmann J M, Brown W D and Hacein-Bey L 2001 Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging AJNR Am J Neuroradiol 22 1813–24

[14]     Dighriri I M, Alsubaie A M, Hakami F M, Hamithi D M, Alshekh M M, Khobrani F A, Dalak F E, Hakami A A, Alsueaadi E H, Alsaawi L S, Alshammari S F, Alqahtani A S, Alawi I A, Aljuaid A A and Tawhari M Q 2022 Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions: A Systematic Review Cureus

[15]     Arellanes I C, Choe N, Solomon V, He X, Kavin B, Martinez A E, Kono N, Buennagel D P, Hazra N, Kim G, D’Orazio L M, McCleary C, Sagare A, Zlokovic B V, Hodis H N, Mack W J, Chui H C, Harrington M G, Braskie M N, Schneider L S and Yassine H N 2020 Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial eBioMedicine 59

[16]     Wei B-Z, Li L, Dong C-W, Tan C-C, Alzheimer’s Disease Neuroimaging Initiative and Xu W 2023 The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers Am J Clin Nutr 117 1096–109

[17]     Power R, Nolan J M, Prado-Cabrero A, Roche W, Coen R, Power T and Mulcahy R 2022 Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial Clinical Nutrition 41 405–14

[18]     Ajith T A 2018 A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease Current Clinical Pharmacology 13 252–60

[19]     Patrick R P 2019 Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer’s disease FASEB J 33 1554–64

[20]     Valente M, Dentoni M, Bellizzi F, Kuris F and Gigli G L 2022 Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications Molecules 27 4836

[21]     Francos-Quijorna I, Santos-Nogueira E, Gronert K, Sullivan A B, Kopp M A, Brommer B, David S, Schwab J M and López-Vales R 2017 Maresin 1 Promotes Inflammatory Resolution, Neuroprotection, and Functional Neurological Recovery After Spinal Cord Injury J. Neurosci. 37 11731–43

[22]     Yang A C, Stevens M Y, Chen M B, Lee D P, Stähli D, Gate D, Contrepois K, Chen W, Iram T, Zhang L, Vest R T, Chaney A, Lehallier B, Olsson N, du Bois H, Hsieh R, Cropper H C, Berdnik D, Li L, Wang E Y, Traber G M, Bertozzi C R, Luo J, Snyder M P, Elias J E, Quake S R, James M L and Wyss-Coray T 2020 Physiological blood-brain transport is impaired with age by a shift in transcytosis Nature 583 425–30

[23]     Kris-Etherton P, Taylor D S, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove R L, Zhao G and Etherton T D 2000 Polyunsaturated fatty acids in the food chain in the United States12 The American Journal of Clinical Nutrition 71 179S-188S

[24]     Ziaei S, Mohammadi S, Hasani M, Morvaridi M, Belančić A, Daneshzad E, Saleh S A K, Adly H M and Heshmati J 2024 A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF) Nutr Neurosci 27 715–25

[25]     Brown S P, Mathur B N, Olsen S R, Luppi P-H, Bickford M E and Citri A 2017 New Breakthroughs in Understanding the Role of Functional Interactions between the Neocortex and the Claustrum J. Neurosci. 37 10877–81

[26]     Miranda M, Morici J F, Zanoni M B and Bekinschtein P 2019 Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain Front. Cell. Neurosci. 13

[27]     Zhang Z, Liu X, Schroeder J P, Chan C-B, Song M, Yu S P, Weinshenker D and Ye K 2014 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease Neuropsychopharmacology 39 638–50

[28]     Weinstein G, Beiser A S, Choi S H, Preis S R, Chen T C, Vorgas D, Au R, Pikula A, Wolf P A, DeStefano A L, Vasan R S and Seshadri S 2014 Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study JAMA Neurol 71 55–61

[29]     Parhizkar S and Holtzman D M 2022 APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease Seminars in Immunology 59 101594

[30]     Wierenga K A and Pestka J J 2021 Omega-3 Fatty Acids And Inflammation - You Are What You Eat! Front Young Minds 9 601068

[31]     Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund L-O, Salem Jr N and Palmblad J 2014 Transfer of omega-3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study Journal of Internal Medicine 275 428–36

[32]     Wang Z, Zhang Z, Liu J, Guo M and Li H 2023 Panax Ginseng in the treatment of Alzheimer’s disease and vascular dementia Journal of Ginseng Research 47 506–14

[33]     Lee B C, Choe Y M, Suh G-H, Choi I-G, Kim H S, Hwang J, Yi D, Jhoo J H and Kim J W 2023 Ginseng intake and Alzheimer disease-specific cognition in older adults according to apolipoprotein ε4 allele status Front. Aging Neurosci. 15

[34]     Zhang S, Liu F, Li J, Jing C, Lu J, Chen X, Wang D, Cao D, Zhao D and Sun L 2023 A 4.7-kDa polysaccharide from Panax ginseng suppresses Aβ pathology via mitophagy activation in cross-species Alzheimer’s disease models Biomedicine & Pharmacotherapy 167 115442

[35]     Kim J, Kim S H, Lee D-S, Lee D-J, Kim S-H, Chung S and Yang H O 2013 Effects of fermented ginseng on memory impairment and β-amyloid reduction in Alzheimer’s disease experimental models J Ginseng Res 37 100–7

[36]     Lee M R, Yun B S, In O H and Sung C K 2011 Comparative Study of Korean White, Red, and Black Ginseng Extract on Cholinesterase Inhibitory Activity and Cholinergic Function J Ginseng Res 35 421–8

[37]     Heo J-H, Park M-H and Lee J-H 2016 Effect of Korean Red Ginseng on Cognitive Function and Quantitative EEG in Patients with Alzheimer’s Disease: A Preliminary Study The Journal of Alternative and Complementary Medicine 22 280–5

[38]     Heo J-H, Lee S-T, Oh M J, Park H-J, Shim J-Y, Chu K and Kim M 2011 Improvement of Cognitive Deficit in Alzheimer’s Disease Patients by Long Term Treatment with Korean Red Ginseng J Ginseng Res 35 457–61

[39]     Belloy M E, Napolioni V and Greicius M D 2019 A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward Neuron 101 820–38

[40]     Yamazaki Y, Zhao N, Caulfield T R, Liu C-C and Bu G 2019 Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies Nat Rev Neurol 15 501–18

[41]     Ba M, Kong M, Li X, Ng K P, Rosa-Neto P and Gauthier S 2016 Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease? Transl Neurodegener 5 20

[42]     Platt M P, Agalliu D and Cutforth T 2017 Hello from the Other Side: How Autoantibodies Circumvent the Blood–Brain Barrier in Autoimmune Encephalitis Front. Immunol. 8

[43]     LeVine S M 2016 Albumin and multiple sclerosis BMC Neurol 16 47

[44]     Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund L-O and Palmblad J 2006 ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial Arch Neurol 63 1402–8

[45]     Quinn J F, Raman R, Thomas R G, Yurko-Mauro K, Nelson E B, Van Dyck C, Galvin J E, Emond J, Jack C R, Weiner M, Shinto L and Aisen P S 2010 Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA 304 1903–11

[46]     Xiang Y, Wang S, Wang L, Wang Z, Yao H, Chen L and Wang Y 2019 Effects of Ginsenoside Rg1 Regulating Wnt/ β -Catenin Signaling on Neural Stem Cells to Delay Brain Senescence Stem Cells International 2019 1–12

[47]     Gong L, Yin J, Zhang Y, Huang R, Lou Y, Jiang H, Sun L, Jia J and Zeng X 2022 Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases Front. Pharmacol. 13

[48]     Shi H, Zhao J, Li Y, Li J, Li Y, Zhang J, Qiu Z, Wu C, Qin M, Liu C, Zeng Z, Zhang C and Gao L 2023 Ginsenosides Rg1 regulate lipid metabolism and temperature adaptation in Caenorhabditis elegans Journal of Ginseng Research 47 524–33

[49]     Delui M H, Fatehi H, Manavifar M, Amini M, Ghayour-Mobarhan M, Zahedi M and Ferns G 2013 The Effects of Panax Ginseng on Lipid Profile, Pro-oxidant: Antioxidant Status and High-sensitivity C Reactive Protein Levels in Hyperlipidemic Patients in Iran Int J Prev Med 4 1045–51

[50]     Yu X, Li H, Lin D, Guo W, Xu Z, Wang L and Guan S 2021 Ginsenoside Prolongs the Lifespan of C. elegans via Lipid Metabolism and Activating the Stress Response Signaling Pathway International Journal of Molecular Sciences 22

[51]     Sofela S, Sahloul S and Song Y-A 2021 Biophysical analysis of drug efficacy on C. elegans models for neurodegenerative and neuromuscular diseases PLOS ONE 16 e0246496

[52]     Alvarez J, Alvarez-Illera P, Santo-Domingo J, Fonteriz R I and Montero M 2022 Modeling Alzheimer’s Disease in Caenorhabditis elegans Biomedicines 10 288

[53]     Alexander A G, Marfil V and Li C 2014 Use of Caenorhabditis elegans as a model to study Alzheimer’s disease and other neurodegenerative diseases Front. Genet. 5

[54]     Carmichael O T, Pillai S, Shankapal P, McLellan A, Kay D G, Gold B T and Keller J N 2018 A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults The Journal of nutrition, health and aging 22 837–46

[55]     Lee J, Lee A, Kim J-H, Shin Y M, Kim S-J, Cho W D and Lee S I 2020 Effect of Omega-3 and Korean Red Ginseng on Children with Attention Deficit Hyperactivity Disorder: An Open-Label Pilot Study Clin Psychopharmacol Neurosci 18 75–80

[56]     Tangrodchanapong T, Sobhon P and Meemon K 2020 Frondoside A Attenuates Amyloid-β Proteotoxicity in Transgenic Caenorhabditis elegans by Suppressing Its Formation Front. Pharmacol. 11

[57]     Bhatia S, Rawal R, Sharma P, Singh T, Singh M and Singh V 2022 Mitochondrial Dysfunction in Alzheimer’s Disease: Opportunities for Drug Development Curr Neuropharmacol 20 675–92

[58]     Sweeney M D, Sagare A P and Zlokovic B V 2018 Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders Nat Rev Neurol 14 133–50

[59]     Cline E N, Bicca M A, Viola K L and Klein W L 2018 The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade Journal of Alzheimer’s Disease 64 S567–610

[60]     Rashad A, Rasool A, Shaheryar M, Sarfraz A, Sarfraz Z, Robles-Velasco K and Cherrez-Ojeda I 2022 Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials Healthcare (Basel) 11 32

[61]     Sims J R, Zimmer J A, Evans C D, Lu M, Ardayfio P, Sparks J, Wessels A M, Shcherbinin S, Wang H, Monkul Nery E S, Collins E C, Solomon P, Salloway S, Apostolova L G, Hansson O, Ritchie C, Brooks D A, Mintun M, Skovronsky D M, and TRAILBLAZER-ALZ 2 Investigators 2023 Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial JAMA 330 512–27

[62]     Anon Strain: CL2355, Genotype: smg-1(cc546) dvIs50 I. - Caenorhabditis Genetics Center (CGC) - College of Biological Sciences

[63]     Yarizadeh H, Hassani B, Nosratabadi S, Baharlooi H, Asadi S, Bagherian S A, Islam S, Djafarian K and Mirzaei K 2021 The Effects of Omega-3 Supplementation on Resting Metabolic Rate: A Systematic Review and Meta-Analysis of Clinical Trials Evidence-Based Complementary and Alternative Medicine 2021 6213035

[64]     Margie O, Palmer C and Chin-Sang I 2013 C. elegans Chemotaxis Assay J Vis Exp 50069

[65]     Hart A C 2006 Behavior WormBook: The Online Review of C. elegans Biology [Internet] (WormBook)

[66]     Lee M, Lee S-H, Kim M-S, Ahn K-S and Kim M 2022 Effect of Lactobacillus dominance modified by Korean Red Ginseng on the improvement of Alzheimer’s disease in mice Journal of Ginseng Research 46 464–72

[67]     Lim S W, Shin Y J, Luo K, Quan Y, Cui S, Ko E J, Chung B H and Yang C W 2019 Ginseng increases Klotho expression by FoxO3-mediated manganese superoxide dismutase in a mouse model of tacrolimus-induced renal injury Aging (Albany NY) 11 5548–69

[68]     Château M-T, Araiz C, Descamps S and Galas S 2010 Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in Caenorhabditis elegans Aging (Albany NY) 2 567–81

[69]     Chávez-Castillo M, Gotera M P, Duran P, Díaz M P, Nava M, Cano C, Díaz-Camargo E, Cano G, Cano R, Rivera-Porras D and Bermúdez V 2025 Neuroprotective Role of Omega-3 Fatty Acids: Fighting Alzheimer’s Disease Molecules 30

[70]     Watts J L 2016 Using Caenorhabditis elegans to Uncover Conserved Functions of Omega-3 and Omega-6 Fatty Acids Journal of Clinical Medicine 5